Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 8,165 matching trials from the live ClinicalTrials.gov search.

Filters: Phoenix, Arizona Clear all

Conditions: Non-Hodgkin's Lymphoma
Interventions: Idasanutlin, Obinutuzumab, Rituximab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 8
States / cities: Phoenix, Arizona • Aurora, Colorado • Louisville, Kentucky + 5 more

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: C11-Sodium Acetate; Drug
Lead sponsor: Phoenix Molecular Imaging; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Cholera
Interventions: PXVX0200 Lot A, PXVX0200 Lot B, PXVX0200 Lot C, Placebo; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 3,146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 19
States / cities: Mobile, Alabama • Phoenix, Arizona • DeLand, Florida + 15 more

Conditions: Smoking, Tobacco
Interventions: P1213416, P1213422, P1213716, P1213722, P1211216, P1211222, P1213616, P1213622, P1213816, P1213822, P1211916, P1211922; Other
Lead sponsor: RAI Services Company; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 1,845 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 12
States / cities: Phoenix, Arizona • Fort Lauderdale, Florida • Orlando, Florida + 9 more

Conditions: Heart Failure
Interventions: COGNIS CRT-D; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 81
States / cities: Anchorage, Alaska • Gilbert, Arizona • Little Rock, Arizona + 69 more

Conditions: Crohn's Disease, IBD
Interventions: Brazikumab low dose, Brazikumab high dose, Humira®, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 38
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Lancaster, California + 31 more

Conditions: Cervical Dystonia
Interventions: MTR-601, Placebo; Drug
Lead sponsor: Motric Bio; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 17
States / cities: Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 14 more

Conditions: High Triglycerides
Interventions: NST-1024, Placebo; Drug · Other
Lead sponsor: NorthSea Therapeutics B.V.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 31
States / cities: Birmingham, Alabama • Daphne, Alabama • Tempe, Arizona + 28 more

Conditions: Head and Neck Cancer, Radiation Toxicity
Interventions: radioprotection, radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2016
U.S. locations: 15
States / cities: Phoenix, Arizona • San Francisco, California • Gainesville, Florida + 12 more

Conditions: Diabetic Retinopathy
Interventions: AKST4290, Placebo; Drug
Lead sponsor: Alkahest, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 17
States / cities: Phoenix, Arizona • Glendale, California • Huntington Beach, California + 13 more

Conditions: Asthma
Interventions: Atuliflapon, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 64
States / cities: Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 52 more

Conditions: Refractory Partial Seizures
Interventions: E2007 (perampanel), Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 32
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 17 more

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions: Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg), Placebo to match metoprolol succinate; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 28
States / cities: Anchorage, Alaska • Phoenix, Arizona • La Jolla, California + 21 more

Conditions: Otitis Media in Patients With Tympanostomy Tubes
Interventions: Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension, CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%), Placebo Sterile Otic Suspension; Drug
Lead sponsor: Par Pharmaceutical, Inc.; Industry
Eligibility: 6 Months to 12 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 23
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 17 more

Conditions: Bipolar I or II Disorder
Interventions: ABBV-932; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 47
States / cities: Phoenix, Arizona • Anaheim, California • Colton, California + 41 more

Conditions: Infrarenal Abdominal Aortic Aneurysm
Interventions: Anaconda Stent Graft System, Anaconda ONE-LOK Stent Graft System; Device
Lead sponsor: Terumo CVS; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 18
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Long Beach, California + 14 more

Conditions: Lung Transplant
Interventions: Tocilizumab, Placebo for Tocilizumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 21
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more

Conditions: Chronic Kidney Disease, Left Ventricular Hypertrophy
Interventions: paricalcitol, placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 30
States / cities: Phoenix, Arizona • Tempe, Arizona • San Diego, California + 24 more

Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma, Locally Recurrent Laryngeal Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oropharyngeal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Melanoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Unresectable Melanoma
Interventions: Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Nivolumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 232
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 179 more

Conditions: Autoimmune Diseases of the Nervous System, Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Disease Progression, Brain Atrophy
Interventions: Tcelna, Placebo; Biological
Lead sponsor: Opexa Therapeutics, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 33
States / cities: Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 28 more

Conditions: Diabetic Foot Ulcers
Interventions: Epiflo, Moist Wound Therapy; Device · Other
Lead sponsor: Neogenix, LLC dba Ogenix; Industry
Eligibility: 20 Years to 90 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 14
States / cities: Phoenix, Arizona • Tucson, Arizona • Encinitas, California + 11 more

Conditions: Prostate Cancer
Interventions: Plenaxis; Drug
Lead sponsor: PRAECIS Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 60
States / cities: Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 54 more

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: PF-06821497, Placebo, Enzalutamide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 39
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 25 more

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Refractory Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Tuvusertib, Ultrasound Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 26
States / cities: Phoenix, Arizona • Orange, California • Aventura, Florida + 19 more

Search by objective public record fields.

A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma

A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults

CSD201204 An Actual Use Study of P12 Electronic Nicotine Delivery System Among U.S. Adult Smokers

Evaluation of Multisensor Data in Heart Failure Patients With Implanted Devices

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease

Study of the Oral Treatment MTR-601 in Cervical Dystonia

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia

Radiation Therapy in Treating Patients With Stage II or Stage III Oropharyngeal Cancer

A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

To Evaluate The Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

The Vascutek AnacondaTM Stent Graft System Phase II IDE Study

Tocilizumab in Lung Transplantation

The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis

Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers

The Plenaxis® Experience Study

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer